Review Article
New Insight into the Treatment of Advanced Differentiated Thyroid Cancer
Table 1
Trials of tyrosine kinase inhibitors in patients with metastatic differentiated thyroid cancer.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BRAF: B isoform of Raf kinase; DTC: differentiated thyroid cancer; PDGFR: platelet-derived growth factor receptor; VEGFR: vascular endothelial growth factor receptor; NR: not reported; mos: months; wks: weeks; RECIST: response evaluation criteria in solid tumors; CR: complete response; PR: partial response; SD: stable disease; PFS: progression-free survival time. Note: vandetanib is not shown in the table. |